Fresenius/€FRE

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Fresenius

Fresenius SE & Co. KGaA, operating under the ticker FRE, is a global healthcare group founded in 1912. The company specializes in products and services for dialysis, hospitals, and outpatient medical care. Operating in the healthcare sector, Fresenius provides a range of services including engineering and services for hospitals and other healthcare facilities.

Ticker

€FRE
Sector

Primary listing

XETRA

Employees

176,207

Fresenius Metrics

BasicAdvanced
€27B
23.60
€2.00
0.95
€1.00
2.12%

What the Analysts think about Fresenius

Analyst ratings (Buy, Hold, Sell) for Fresenius stock.

Bulls say / Bears say

Fresenius has raised its 2025 organic revenue growth target to 5–7%, up from 4–6%, and reported Q2 EBIT of €654 million, beating analysts’ consensus by 2.6%, reflecting strong demand in its main businesses and successful restructuring efforts. (Reuters)
For Q1 2025, Fresenius recorded EBIT of €654 million, above the Vara Research consensus of €634 million, driven by strong results from its Fresenius Kabi pharmaceutical unit and strengthening confidence in its full-year outlook. (Reuters)
Proceeds from a planned proportional sale of €1 billion in Fresenius Medical Care shares, to maintain a roughly 28.6% stake, will be reinvested as part of the #FutureFresenius strategy in high-growth areas such as Fresenius Kabi and hospital operator Helios, aiming for better capital efficiency. (Reuters)
Fresenius Medical Care’s Q2 earnings fell short of expectations, with U.S. same-market dialysis treatment growth stagnating and full-year guidance lowered to flat or only slightly positive, highlighting Fresenius’s dependence on the volatile dialysis business. (Reuters)
A roughly 10% appreciation of the euro since March 2025 is projected to reduce earnings by 2–3% for export-focused companies such as Fresenius, putting pressure on global competitiveness and margins. (Reuters)
In the wake of FMC’s Q2 earnings miss, its share price dropped around 4%, implying Fresenius could face mark-to-market losses on its planned share sale to maintain its stake, potentially limiting available funds for key investments. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

Fresenius Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Fresenius Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FRE

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs